-
21
-
22
-
23
Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases
Published 2025-01-01Get full text
Article -
24
Advances in Object Detection and Localization Techniques for Fruit Harvesting Robots
Published 2025-01-01Get full text
Article -
25
-
26
Athermal Tantalum Pentoxide Mach-Zehnder Interferometers Based on Structural Compensation Method
Published 2025-01-01Get full text
Article -
27
Mechanistic insight into human milk extracellular vesicle‐intestinal barrier interactions
Published 2025-01-01Get full text
Article -
28
-
29
-
30
The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
Published 2025-01-01Get full text
Article -
31
-
32
Medication adherence among hospitalized hypertension patients in Shenyang city
Published 2024-12-01Get full text
Article -
33
-
34
Sources and Health Risks of PM2.5-bound PAHs in a Small City along with the “Clean Heating” Policy
Published 2022-06-01Get full text
Article -
35
Variations in Sources, Composition, and Exposure Risks of PM2.5 in both Pre-Heating and Heating Seasons
Published 2022-01-01Get full text
Article -
36
-
37
-
38
-
39
-
40
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
Published 2025-01-01“…Xiaowei Li,* Kunkun Cao,* Zhigang Fu,* Xiaoxia Chen, Jiaming Zhong, Li Liu, Ning Ding, Xiaoli Zhang, Zengqiang Qu, Lijun Zhu, Jian Zhai Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jian Zhai; Lijun Zhu, Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China, Email jianzhai1979@126.com; lijun_zhush@163.comPurpose: To assess the activity and toxicity of hepatic arterial infusion chemotherapy (HAIC)+tislelizumab+lenvatinib (HAIC+tisle+len) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) type IV (Vp4 hCC) in a real-world context.Methods: Fifty-five patients, with Vp4 hCC receiving HAIC+tisle+len therapy from April 2021 to December 2022, were analyzed retrospectively. …”
Get full text
Article